HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Ioxilan

HCID 3743
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
107793-72-6
Standard SMILES
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I
InChIKey
UUMLTINZBQPNGF-UHFFFAOYSA-N
Molecular formula
C18H24I3N3O8
Average molar mass
791.1 g/mol
Monoisotopic mass
790.8698

Overview

Ioxilan is an amidobenzoic acid.

Names & identifiers

Preferred name
Ioxilan
IUPAC
5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
English name
IOXILAN (400 MG)
Molecular formula
C18H24I3N3O8
Molecular weight
791.11

Names & synonyms

ioxilan107793-72-6OxilanIoxitolIoxilaneIoxilanumOxilan-300Oxilan-350LoxilanDTXSID0048717A4YJ7J11TGNSC-760056
Show more names
Oxilan 300IOXILAN (400 MG)Ioxilan (1345206)5-[Acetyl(2,3-dihydroxypropyl)aMino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodo-1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo-5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
N-(2,3-Dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-N'-(2-hydroxyethyl)-2,4,6-triiodoisophthalamideDTXCID70286431,3-Benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodo-N1-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-N3-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamideN1-(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-N3-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamideRefChem:57668V08AB125-(N-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-N-(2-hydroxyethyl)-N'-(2,3-dihydroxypropyl)isophthalamide

Properties

Computed structural propertiesFilling in

XLogP
-2.4
Topological polar surface area
180 Ų
Hydrogen bond donors
7
Hydrogen bond acceptors
8
Rotatable bonds
11
Heavy atoms
32
Formal charge
0
Complexity
647

Experimental & physicochemical properties

Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physicochemical properties

Boiling point
827.8 · 827.8±65.0 °C(Predicted)
Density
2.205 · 2.205±0.06 g/cm3(Predicted)
storage temp.
-20 °C · Store at -20°C
solubility
250 mg/mL · DMSO: ≥ 250 mg/mL (316.01 mM)
pka
11.47 · 11.47±0.46(Predicted)
form
Solid
color
White to off-white
Major Application
pharmaceutical (small molecule)
InChI
1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
WGK 3
hs_code
2924296000
Storage Class
11 - Combustible Solids

Chemistry & industry

Pharmacology

ATC Code · 2 items

V - Various

QV - Various

Protein BindingBinding of ioxilan to plasma protein is negligible.
PharmacodynamicsAs with other iodinated contrast agents the degree of contrast enhancement is directly related to the iodine content in the administered dose.
Mechanism of ActionIntravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs.
Biological Half-LifeAn initial fast distribution phase with a half-life of 13.1 ± 4.2 minutes (women) or 23.5 ± 15.3 minutes (men) was followed by an elimination phase with a half-life of 102.0 ± 16.9 minutes (women) and 137 ± 35.4 minutes (men).
Metabolism/MetabolitesThere is no evidence for metabolism.
FDA Pharmacological Classification · 5 items

A4YJ7J11TG

IOXILAN

Established Pharmacologic Class [EPC] - Radiographic Contrast Agent

Mechanisms of Action [MoA] - X-Ray Contrast Activity

Ioxilan is a Radiographic Contrast Agent. The mechanism of action of ioxilan is as a X-Ray Contrast Activity.

MeSH Pharmacological ClassificationSubstances used to allow enhanced visualization of tissues.
Absorption, Distribution and Excretion · 4 items

Peak iodine plasma levels occur immediately following rapid intravenous injection. Iodine plasma levels fall rapidly within 5 to 10 minutes. This can be accounted for by the dilution in the vascular and extravascular fluid compartments.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
107793-72-6
PubChem CID
3743
DTXSID
DTXSID0048717
ChEMBL
CHEMBL1201075
ChEBI
CHEBI:135884
UNII
A4YJ7J11TG
Nikkaji
J518.532G
InChIKey
UUMLTINZBQPNGF-UHFFFAOYSA-N
SMILES
Ic1c(c(c(c(c1C(=O)NCC(O)CO)I)C(=O)NCCO)I)N(CC(O)CO)C(=O)C
FDA UNII
4 YJ7J11TG · A4YJ7J11TG
EPA Substance Registry System
1 · 1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo- (107793-72-6)
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
WGK Germany
3 · WGK 3
HS Code
2924296000 · 2924296000
Storage Class
11 · 11 - Combustible Solids

The average amount of ioxilan excreted unchanged in urine at 24 hours represents 93.7% of the dose in young healthy subjects (21-27 years) after intravenous administration. This finding suggests that, compared to the renal excretion, biliary and/or gastrointestinal excretion are not important.

Ioxilan is distributed mainly in the blood as suggested by the apparent volume of distribution (central compartment), 7.2 ± 1.0 L in women and 10.0 ± 2.4 L in men

The total clearance values were 95.4 ± 11.1 mL·min-1 and 101.0 ± 14.7 mL·min-1 and the renal clearance values were 89.4 ± 13.3 mL·min-1 and 94.9 ± 16.6 mL·min-1 for women and men, respectively.

Applications

UsesNonionic iodinated contrast medium. Diagnostic aid (radiopaque medium).

Additional notes

DefinitionChEBI: Ioxilan is an amidobenzoic acid.